{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:27:04Z","timestamp":1793330824219,"version":"4.5.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"\n Importance<\/jats:title>\n The prevalence of obesity and cardiovascular-kidney-metabolic (CKM) syndrome continues to rise. Indications for novel CKM therapies, including glucagonlike peptide 1 receptor agonists (GLP-1RAs), sodium-glucose cotransporter-2 inhibitors (SGLT2is), and nonsteroidal mineralocorticoid antagonists (nsMRAs) continue to expand, yet the proportion of adults meeting expanded indications, including for multiple medications remains unclear.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine proportion of adults meeting US Food and Drug Administration (FDA)\u2013approved indications for GLP1-RAs, SGLT2is, and nsMRAs across national survey, community-based, and ambulatory health care samples.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This study used a representative cross-sectional survey of US adults (National Health and Nutrition Examination Survey [NHANES], weighted 245 million; mean [SD] age, 47 [18] years; 126.8 million [52%] female), 5 pooled community-based cohort studies (the Framingham Heart Study, the Multi-Ethnic Study of Atherosclerosis, the Prevention of Renal and Vascular Endstage Disease Study, the Atherosclerosis Risk in Communities Study, and the Cardiovascular Health Study; n\u2009=\u200930\u202f929; mean [SD] age, 63 [14] years; 16\u202f749 [54%] female), and 2 ambulatory health care samples (the Beth Israel Deaconess Medical Center cohort [BIDMC], n\u2009=\u200984\u202f714; mean [SD] age, 46 [17] years; 51\u202f113 [60%] female] and the Mass General Brigham cohort [MGB], n\u2009=\u2009362\u202f485; mean [SD] age, 48 [17] years; 227\u202f206 [61%] female). Data were analyzed from November 2024 to November 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n FDA-approved indications for GLP-1RAs, SGLT2is, and nsMRAs.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Medication class eligibility within each study sample.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The proportion of individuals who met current FDA-approved indications for 1 or more CKM medication was 60% in NHANES (representing 148 million US adults), 61% in the pooled cohorts, 42% in the BIDMC ambulatory cohort, and 46% in the MGB ambulatory cohort. Eligibility for GLP-1RA therapy was most common, with 56% (representing 137.1 million US adults) in NHANES, 49% in the pooled cohorts, 41% in the BIDMC cohort, and 46% in the MGB cohort. This was followed by SGLT2i therapy (24% [57.9 million] in NHANES, 33% in the pooled cohorts, 14% for both BIDMC and MGB) and nsMRA (5% [11.7 million] in NHANES, 5% in the pooled cohorts, and 1% to 2% in ambulatory samples). Overlapping eligibility for multiple classes was common, with 12% to 17% for GLP1-RA and SGLT2i therapies and 1% to 5% for all 3 classes (an estimated 11.7 million US adults in NHANES).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This study found that up to 61% of adults met FDA-approved indications for at least 1 of 3 novel CKM therapy classes. This represents an estimated 148 million US adults, including 11.7 million US adults with potential FDA indications for triple therapy, highlighting the urgent need to optimize implementation and utilization of CKM syndrome therapies.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamacardio.2025.5305","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T16:31:24Z","timestamp":1769617884000},"page":"250","source":"Crossref","is-referenced-by-count":9,"title":["Cardiovascular-Kidney-Metabolic Medication Eligibility Across National Survey, Community-Based, and Ambulatory Healthcare Samples"],"prefix":"10.1001","volume":"11","author":[{"given":"Louisa A.","family":"Mounsey","sequence":"first","affiliation":[{"name":"Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Division of Pulmonary, Critical Care, and Sleep, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Chitsazan","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivy","family":"Shi","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts"},{"name":"Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro H.","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Division of Cardiology, Mass General Bringham, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhi K.","family":"Parekh","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athar","family":"Roshandelpoor","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiadi","family":"Ndumele","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norrina B.","family":"Allen","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadiya S.","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce M.","family":"Psaty","sequence":"additional","affiliation":[{"name":"Cardiovascular Health Research Unit, Department of Medicine and Epidemiology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Floyd","sequence":"additional","affiliation":[{"name":"Cardiovascular Health Research Unit, Department of Medicine and Epidemiology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Levy","sequence":"additional","affiliation":[{"name":"Population Sciences Branch, National Heart, Lung and Blood Institute, Framingham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thorax Center, Erasmus University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin","family":"Suthahar","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thorax Center, Erasmus University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Damman","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle C.","family":"Odden","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron T.","family":"Gansevoort","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Medical Center Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Hamo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, New York University School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issa J.","family":"Dahabreh","sequence":"additional","affiliation":[{"name":"Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts"},{"name":"Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts"},{"name":"CAUSALab, Harvard T. H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Yeh","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnaz","family":"Maddah","sequence":"additional","affiliation":[{"name":"Data Sciences Platform, Broad Institute of Harvard and the Massachusetts Institute of Technology, Cambridge"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaan","family":"Khurshid","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mass General Bringham, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick T.","family":"Ellinor","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mass General Bringham, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily S.","family":"Lau","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mass General Bringham, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv S.","family":"Kazi","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Ho","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"20","key":"hoi250080r1","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association.","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"20","key":"hoi250080r2","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association.","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"7","key":"hoi250080r3","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1681\/ASN.0000000637","article-title":"Cumulative incidence of mortality associated with cardiovascular-kidney-metabolic (CKM) syndrome.","volume":"36","author":"Claudel","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"hoi250080r4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1161\/ATVBAHA.124.321629","article-title":"Sex differences in cardiovascular-kidney-metabolic syndrome: 30-year US trends and mortality risks-brief report.","volume":"45","author":"Ji","year":"2025","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"21","key":"hoi250080r5","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1001\/jama.2024.6892","article-title":"Prevalence of cardiovascular-kidney-metabolic syndrome stages in US adults, 2011-2020.","volume":"331","author":"Aggarwal","year":"2024","journal-title":"JAMA"},{"issue":"23","key":"hoi250080r6","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"hoi250080r7","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes.","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"hoi250080r8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/jamacardio.2024.4657","article-title":"Semaglutide eligibility across all current indications for US adults.","volume":"10","author":"Shi","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"8","key":"hoi250080r9","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1111\/dom.13738","article-title":"Eligibility of patients with type 2 diabetes for sodium-glucose co-transporter-2 inhibitor cardiovascular outcomes trials: an assessment using the Diabetes Collaborative Registry.","volume":"21","author":"Wittbrodt","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"hoi250080r10","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1177\/2047487317729252","article-title":"Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: an NCDR Research to Practice project.","volume":"24","author":"Arnold","year":"2017","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"hoi250080r12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.115.003116","article-title":"Predicting heart failure with preserved and reduced ejection fraction: the international collaboration on heart failure subtypes.","volume":"9","author":"Ho","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"1","key":"hoi250080r13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41746-022-00590-0","article-title":"Cohort design and natural language processing to reduce bias in electronic health records research.","volume":"5","author":"Khurshid","year":"2022","journal-title":"NPJ Digit Med"},{"issue":"12","key":"hoi250080r14","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/jama.2024.18219","article-title":"GLP-1 medication use for type 2 diabetes has soared.","volume":"332","author":"Hegland","year":"2024","journal-title":"JAMA"},{"issue":"4","key":"hoi250080r16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US.","volume":"4","author":"Eberly","year":"2021","journal-title":"JAMA Netw Open"},{"key":"hoi250080r17","doi-asserted-by":"publisher","first-page":"q1645","DOI":"10.1136\/bmj.q1645","article-title":"GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment.","volume":"386","author":"Mahase","year":"2024","journal-title":"BMJ"},{"issue":"25","key":"hoi250080r19","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1056\/NEJMp2303268","article-title":"Equity and obesity treatment-expanding Medicaid-covered interventions.","volume":"388","author":"Stoops","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"hoi250080r21","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1001\/jamacardio.2025.3109","article-title":"Discontinuation of semaglutide among older adults with diabetes in the US and Japan.","volume":"10","author":"Inoue","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"2","key":"hoi250080r22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1001\/jama.2024.22284","article-title":"Discontinuation of glucagon-like peptide-1 receptor agonists.","volume":"333","author":"Khan","year":"2025","journal-title":"JAMA"},{"key":"hoi250080r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100617","article-title":"Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021.","volume":"29","author":"Malik","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"hoi250080r24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ahj.2024.12.006","article-title":"Discontinuation of SGLT-2i and GLP-1RA among persons with type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics.","volume":"282","author":"Nelson","year":"2025","journal-title":"Am Heart J"},{"issue":"24","key":"hoi250080r25","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes.","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"hoi250080r26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"hoi250080r27","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1001\/jamacardio.2019.3080","article-title":"Occurence of first and recurrent major adverse cardiovascular events with liraglutide treatment among patients with type 2 diabetes and high risk of cardiovascular events: a post hoc analysis of a randomized clinical trial.","volume":"4","author":"Verma","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"7","key":"hoi250080r28","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"hoi250080r29","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"10","key":"hoi250080r30","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"22","key":"hoi250080r31","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"hoi250080r11","unstructured":"Tutorials? NHANES. Accessed March 24, 2025. https:\/\/wwwn.cdc.gov\/nchs\/nhanes\/tutorials\/default.aspx"},{"key":"hoi250080r15","unstructured":"Montero? ASG, Presiado? M. KFF health tracking poll May 2024: the public\u2019s use and views of GLP-1 drugs. Accessed May 27, 2025. https:\/\/www.kff.org\/health-costs\/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs\/"},{"key":"hoi250080r18","unstructured":"Wreschnig? LA. Medicare coverage of GLP-1 drugs. Accessed May 28, 2025. https:\/\/www.congress.gov\/crs-product\/IF12758#"},{"key":"hoi250080r20","unstructured":"D G. Patients navigate an \u2018absolutely insane\u2019 maze to afford weight-loss drugs. The Washtington Post. Accessed May 28, 2025. https:\/\/www.washingtonpost.com\/business\/2025\/05\/24\/weight-loss-drugs-insurance-coverage\/"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2844100\/jamacardiology_mounsey_2026_oi_250080_1773061326.35799.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T15:00:54Z","timestamp":1773241254000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2844100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2025.5305","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}